Form 4: Tango Therapeutics Director Mace Rothenberg Receives Equity
Statement of Changes in Beneficial Ownership
Director Mace Rothenberg was granted 4,000 restricted stock units and 25,000 stock options by Tango Therapeutics.
Summary
- Director Mace Rothenberg acquired 4,000 restricted stock units (RSUs) on June 5, 2026.
- The director was also granted 25,000 stock options with an exercise price of $20.22.
- The RSUs vest on the earlier of June 5, 2027, or the date of the next annual meeting.
- The stock options vest in 12 equal monthly installments starting July 5, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational outlook.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Standard retention and incentive structure for board members.
Negatives
- Dilutive impact of new equity grants on existing shareholders.
Risks
- Vesting is subject to the director's continuous service with the company.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director compensation.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure alignment between leadership and shareholders, particularly for companies in the clinical development stage.
Comparison to Industry Standards
- The use of a mix of RSUs and stock options is consistent with standard compensation packages for directors in mid-cap biotech firms.
- Vesting schedules of one year for options are relatively aggressive compared to some peers who may use three-to-four-year vesting periods.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Mace Rothenberg authorized Julie Fogarty and Matthew Gall to file SEC documents on his behalf. | 06/07/2026 | Administrative update to facilitate regulatory compliance. |
Stakeholder Impact
- Shareholders: Minor dilution from new equity issuance.
- Director: Increased financial stake in the company's performance.
Next Steps
- Vesting of stock options beginning July 5, 2026.
- Vesting of RSUs on June 5, 2027, or the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 06/05/2026 | Transaction date for RSU and stock option grants. |
| 06/07/2026 | Execution date of the Power of Attorney. |
| 06/08/2026 | Filing date of the Form 4. |
| 07/05/2026 | First vesting date for stock options. |
| 06/05/2027 | Vesting date for restricted stock units. |
| 06/05/2036 | Expiration date for stock options. |
Keywords
Tango Therapeutics, TNGX, Form 4, Director Compensation, Equity Grant, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.